Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Magnetic Resonance Spectroscopy 281Specimen Handling 271pembrolizumab 253Cyclophosphamide 235Radiotherapy 227Nivolumab 184Cisplatin 172Biopsy 161Carboplatin 155Radiosurgery 143fludarabine 131Blood Specimen Collection 129Surveys and Questionnaires 120Gemcitabine 119Paclitaxel 116venetoclax 114Standard of Care 112Dexamethasone 107Bevacizumab 93Radiation 92Rituximab 91Oxaliplatin 89Cytarabine 88Ipilimumab 84Drug Therapy 84Capecitabine 84Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × efineptakin alfa × 90 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT07200089 2026-04-07

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Washington University School of Medicine

Phase 1 Not yet recruiting
52 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡